Type I Diabetes Patents (Class 514/7.3)
-
Publication number: 20140294901Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140286906Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Inventors: Daniel Bilbao Cortes, Nadia Rosenthal, Luisa Luciani
-
Publication number: 20140274892Abstract: The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140249077Abstract: The present invention is directed to compositions and methods of preparation of phospholipid gels.Type: ApplicationFiled: June 8, 2012Publication date: September 4, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Andrew Xian Chen, Hailiang Chen
-
Publication number: 20140249081Abstract: The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona.Type: ApplicationFiled: February 6, 2014Publication date: September 4, 2014Inventors: Thomas Rademacher, Phillip Williams
-
Publication number: 20140249072Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: ApplicationFiled: May 4, 2012Publication date: September 4, 2014Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Publication number: 20140243260Abstract: The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: NEW YORK UNIVERSITYInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140234282Abstract: Compositions and methods comprising ampicillin or salts and derivative thereof for the treatment of delaying the on-set of type I diabetes are provided.Type: ApplicationFiled: September 20, 2012Publication date: August 21, 2014Applicant: STEM CELL MEDICINE LTD.Inventors: Irun R. Cohen, Felix Mor
-
Publication number: 20140234405Abstract: To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Claresa Levetan
-
Publication number: 20140221278Abstract: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 5, 2013Publication date: August 7, 2014Inventor: Yitzchak Hillman
-
Publication number: 20140221287Abstract: There are provided polypeptide conjugates having enhanced duration of biological activity, and methods of use thereof. The polypeptide conjugates include duration enhancing moieties, including water soluble polymers, bound to the polypeptide components of defined sequence. Methods of use are provided for treatment of metabolic disorders. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyper lipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis, osteoarthritis, or short bowel syndrome.Type: ApplicationFiled: May 24, 2012Publication date: August 7, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Chengzao Sun, Manoj P. Samant, Swetha Neravetla
-
Publication number: 20140221271Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.Type: ApplicationFiled: June 5, 2012Publication date: August 7, 2014Inventors: Shawn P Iadonato, Eric J Tarcha
-
Publication number: 20140221277Abstract: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.Type: ApplicationFiled: November 22, 2013Publication date: August 7, 2014Applicant: CARA THERAPEUTICS, INC.Inventors: Frederique Menzaghi, Michael E. Lewis, Derek T. Chalmers
-
Publication number: 20140213512Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided.Type: ApplicationFiled: August 30, 2012Publication date: July 31, 2014Applicant: Amgen Inc.Inventors: Murielle Marie Ellison, Shanaka Stanislaus, Jing Xu
-
Patent number: 8785128Abstract: Disclosed are methods of identifying a genetic variant in a person determined to have or be predisposed having a fatty liver by determining whether the person has PNPLA3-I148M. Also disclosed are methods of identifying a genetic variant in a person by determining whether the person has PNPLA3-I148M; and prescribing to the person a treatment to reduce liver fat or associated inflammation.Type: GrantFiled: November 26, 2012Date of Patent: July 22, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Helen H Hobbs, Jonathan C Cohen
-
Patent number: 8785374Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: GrantFiled: October 20, 2008Date of Patent: July 22, 2014Assignee: Alba Therapeutics CorporationInventor: Amir Tamiz
-
Publication number: 20140194343Abstract: [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. [Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.Type: ApplicationFiled: May 9, 2012Publication date: July 10, 2014Applicant: THE UNIVERSITY OF TOKYOInventors: Yoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
-
Publication number: 20140194352Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: ApplicationFiled: November 26, 2013Publication date: July 10, 2014Applicant: NGM Biopharmaceuticals, Inc.Inventors: Lei Ling, Darrin Anthony Lindhout
-
Patent number: 8759295Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: May 21, 2010Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Publication number: 20140162948Abstract: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.Type: ApplicationFiled: September 26, 2013Publication date: June 12, 2014Applicant: EVOTEC INTERNATIONAL GMBHInventors: Friedrich Harder, Matthias Austen
-
Publication number: 20140155316Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicants: New York University, Salk Institute for Biological StudiesInventors: Moosa Mohammadi, Regina M. Goetz, Ronald M. Evans, Michael Downes, Jae Myoung Suh
-
Publication number: 20140155324Abstract: The invention relates to polypeptides exhibiting metabolic-modulating as well as immunomodulatory properties, nucleic acids encoding them, compositions comprising them, and methods of treating metabolic disorders and/or immune-related disorders comprising their administration and to their use in preparing pharmaceutical compositions for the treatment, amelioration, prophylaxis or delaying the onset of at least one of a metabolic disorder and an immune-related disorder.Type: ApplicationFiled: August 6, 2012Publication date: June 5, 2014Applicant: TWO TO BIOTECH LTD.Inventors: Tamara Sandler, Orly Devary
-
Patent number: 8741836Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 8, 2012Date of Patent: June 3, 2014Assignee: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140147441Abstract: Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an ?1 antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of ?1-antitrypsin.Type: ApplicationFiled: November 19, 2013Publication date: May 29, 2014Applicants: The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Jeffrey Flier, Maria Koulmanda, Terry B. Strom
-
Publication number: 20140128321Abstract: A method for preventing or delaying the onset of autoimmune diseases is disclosed.Type: ApplicationFiled: November 1, 2013Publication date: May 8, 2014Applicant: University of Maryland, BaltimoreInventors: Alessio Fasano, Tammara L. Watts
-
Publication number: 20140120097Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Inventor: Claresa Levetan
-
Patent number: 8703654Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.Type: GrantFiled: August 11, 2011Date of Patent: April 22, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
-
Publication number: 20140107022Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: December 4, 2013Publication date: April 17, 2014Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina GOETZ
-
Patent number: 8691759Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: GrantFiled: March 13, 2009Date of Patent: April 8, 2014Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Janos Tibor Kodra, Patrick William Garibay
-
Patent number: 8691949Abstract: The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or treat diseases caused by hyperglycemia, in particular, diabetes and diabetic complications (a composition for preventing or treating diseases caused by hyperglycemia, an antidiabetic), based on the above-mentioned effect. A feature of the present invention is using a peptide consisting of the amino acid sequence of Leu-Ser-Glu-Leu as an active ingredient.Type: GrantFiled: October 28, 2009Date of Patent: April 8, 2014Assignee: MG Pharma Inc.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Chunning Tong, Yuka Sasakawa
-
Publication number: 20140093519Abstract: Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for cell replacement therapy is desirable, including, e.g., diabetes and conditions that result in loss of all or part of the pancreas.Type: ApplicationFiled: August 1, 2013Publication date: April 3, 2014Inventor: Linda BURKLY
-
Publication number: 20140094406Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140087995Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: NOVO NORDISK A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Publication number: 20140086903Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: ApplicationFiled: March 15, 2013Publication date: March 27, 2014Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
-
Patent number: 8680051Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.Type: GrantFiled: December 21, 2009Date of Patent: March 25, 2014Inventors: Qinghua Wang, Soltani Nepton
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Publication number: 20140066373Abstract: Methods are provided of treating or preventing diabetes in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. Methods are also provided of increasing insulin secretion in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog.Type: ApplicationFiled: August 26, 2013Publication date: March 6, 2014Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Dongsheng Cai
-
Publication number: 20140066370Abstract: The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.Type: ApplicationFiled: November 23, 2010Publication date: March 6, 2014Applicant: Amylin Pharmaceuticals, LLCInventors: Behrouz Bruce Forood, Soumitra S. Ghosh, James L. Trevaskis, Chengzao Sun, Odile Esther Levy, Lawrence J. D'Souza, Christopher J. Soares
-
Publication number: 20140057838Abstract: Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and play a role in glucose metabolism. The present invention relates to methods for treating or preventing diseases such as diabetes, metabolic syndrome, and obesity or obesity-related by administering a therapeutically effective amount of osteoblast-expressed Lcn-2 or a biologically active fragment.Type: ApplicationFiled: April 11, 2012Publication date: February 27, 2014Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventor: Stavroula Kousteni
-
Publication number: 20140057832Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.Type: ApplicationFiled: November 5, 2013Publication date: February 27, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Kirk P. Conrad, Sanjeev G. Shroff
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Patent number: 8637459Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.Type: GrantFiled: November 7, 2007Date of Patent: January 28, 2014Assignee: Emory UniversityInventor: Shanthi Srinivasan
-
Publication number: 20140018286Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicant: NOVO NORDISK A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140011732Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: June 28, 2013Publication date: January 9, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
-
Publication number: 20140005096Abstract: Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease, disorder, condition, or symptom. In some embodiments, the method comprises co-administering an agent that inhibits the interactions of PF4 and RANTES and a second active agent.Type: ApplicationFiled: July 15, 2013Publication date: January 2, 2014Applicant: Carolus Therapeutics, Inc.Inventors: Joshua Robert SCHULTZ, Benedikt VOLLRATH, Court TURNER
-
Publication number: 20140005098Abstract: The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.Type: ApplicationFiled: February 24, 2012Publication date: January 2, 2014Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Jean-François Godeau, Yves Le Bouc
-
Patent number: 8614182Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.Type: GrantFiled: January 31, 2012Date of Patent: December 24, 2013Assignee: Jiangsu Hansoh Pharmaceuticals Co., Ltd.Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Publication number: 20130331317Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: March 15, 2013Publication date: December 12, 2013Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina Goetz